GlaxoSmithKline

Moderna's mResvia RSV vaccine uptake slower than expected, facing challenges from GSK and Pfizer. Moderna executives acknowledge initial optimism and difficulties in contracting and CDC approval.

PDF document structure and metadata, including cross-reference table and stream objects.

Solid tumors market projected to reach $375.4B by 2034 with 7.45% CAGR. Aethlon Medical activates Hemopurifier trial at Royal Adelaide Hospital for solid tumor patients resistant to anti-PD-1 therapies. Immuneering reports positive initial data for IMM-1-104 in pancreatic cancer. FDA approves new immunotherapy combinations for endometrial cancer from AstraZeneca, Merck, and GlaxoSmithKline. Roche's trastuzumab deruxtecan receives accelerated approval for HER2-positive solid tumors.

Japan's health ministry accepts GSK's Blenrep NDA for blood cancer treatment, following EU and UK approvals. Blenrep granted orphan drug status in Japan, supported by DREAMM-7 and DREAMM-8 trials. GSK aims to expedite global regulatory pathways for Blenrep.

Japan's MHLW accepts GSK's NDA for Blenrep plus BorDex or PomDex for relapsed/refractory multiple myeloma, based on DREAMM-7 and DREAMM-8 trials. Blenrep shows potential to redefine treatment landscape.

Kelly Chibale, from a Zambian village to Cambridge and Scripps, founded the Holistic Drug Discovery and Development Centre (H3D) at the University of Cape Town in 2010. H3D, supported by research and funding partners, focuses on malaria, tuberculosis, and antibiotic-resistant diseases, developing MMV390048, the first small-molecule clinical candidate discovered by an Africa-led team. Chibale emphasizes the need for global recognition and collaboration with African scientists to address diverse health challenges and foster innovation.

Moderna revised its break-even forecast from 2026 to 2028, leading to significant R&D cuts and a downgrade in stock ratings by firms like Jefferies and J.P. Morgan. The company plans to focus on 10 pipeline candidates, halting development of five programs, and expects a compounded annual growth rate of over 25% from 2026 to 2028.

GSK and iTeos Therapeutics' Phase II GALAXIES Lung-201 study showed Jemperli and belrestotug, an anti-TIGIT therapy, achieved a 60% objective response rate in non-small cell lung cancer patients, with a 30% improvement over Jemperli alone. The combination also led to significant reductions in circulating tumor DNA and was presented at ESMO 2024.

China's NMPA grants GSK's Blenrep breakthrough therapy designation for relapsed or refractory multiple myeloma treatment, based on Phase III DREAMM-7 trial results showing significant PFS improvements.

NMPA grants Breakthrough Therapy Designation to Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone for relapsed or refractory multiple myeloma, based on phase III DREAMM-7 trial results showing significant PFS improvements. A positive OS trend was observed but not statistically significant at interim analysis.